전체 프로그램

ADC 882 · Antibody 4071 · CGT 2714 · 자동 수집 갱신 권장 · 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved26 programs

데이터 갱신 주기입니다. 갱신 대기 7,666개 보기 · Curated Core는 주간 자동 동기화됩니다.

AntibodyCurated CoreFDAstaleRocheApproved

rituximab (Rituxan)

US label: non-Hodgkin lymphoma, CLL, rheumatoid arthritis, GPA/MPA and pemphigus vulgaris; population-specific indicati… · CD20

#CD20#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 1337Status Approved
CGTLimited DatastalePaolo Caimi, MDPhase 1

BAFF CAR-T (BAFF CAR-T)

Relapsed CLL; Refractory CLL · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 15Status Recruiting
CGTLimited Datastale920th Hospital of Joint Logisti…Phase 1

Anti-CLL1 CART cells (Anti-CLL1 CART cells)

Acute Myeloid Leukemia · Acute Myeloid Leukemia

#AcuteMyeloidLeukemia#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 2Status Active
AntibodyLimited DatastaleGerman CLL Study GroupPhase 2

Alemtuzumab i.v. (Alemtuzumab i.v.)

Chronic Lymphocytic Leukemia · Chronic Lymphocytic Leukemia

#ChronicLymphocyticLeukemia#Antibody#Phase2#monoclonal-antibody#German
Trials 1Status Active
AntibodyLimited DatastaleGerman CLL Study GroupPhase 2

Alemtuzumab s.c. (Alemtuzumab s.c.)

Chronic Lymphocytic Leukemia · Chronic Lymphocytic Leukemia

#ChronicLymphocyticLeukemia#Antibody#Phase2#monoclonal-antibody#German
Trials 1Status Active
CGTLimited DatastaleBeijing BiotechPhase 2

Autologous BCMA/CD19 dual-target CAR-T module (Autologous BCMA/CD19 dual-target CAR-T module)

Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia; Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleBeijing BiotechPhase 2

Autologous BCMA/CD38 dual-target CAR-T module (Autologous BCMA/CD38 dual-target CAR-T module)

Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia; Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL · BCMA

#BCMA#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleBeijing BiotechPhase 2

Autologous BCMA/GPRC5D dual-target CAR-T (Autologous BCMA/GPRC5D dual-target CAR-T)

Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia; Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL · BCMA

#BCMA#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleBeijing BiotechPhase 2

Autologous CD19/CD20 dual-target CAR-T module (Autologous CD19/CD20 dual-target CAR-T module)

Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia; Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleBeijing BiotechPhase 2

Autologous CD19/CD22 dual-target CAR-T module (Autologous CD19/CD22 dual-target CAR-T module)

Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia; Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleBeijing BiotechPhase 2

Autologous CD33/CD123 dual-target CAR-T module (Autologous CD33/CD123 dual-target CAR-T module)

Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia; Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL · CD33

#CD33#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleBeijing BiotechPhase 2

Autologous CD33/CLL1 dual-target CAR-T module (Autologous CD33/CLL1 dual-target CAR-T module)

Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia; Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL · CD33

#CD33#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleBeijing BiotechPhase 2

Autologous CD5/CD7 dual-target CAR-T module (Autologous CD5/CD7 dual-target CAR-T module)

Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia; Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL · FRα

#FR#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleHangzhou Qihan Biotech Co., Ltd.Phase 1

CD33/CLL1 dual CAR-NK cell (CD33/CLL1 dual CAR-NK cell)

AML, Adult; Minimal Residual Disease · CD33

#CD33#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 1Status Active
CGTLimited DatastaleShenzhen Geno-Immune Medical In…Phase 2

CLL-1, CD33 and/or CD123-specific CAR gene-engineered T cells (CLL-1, CD33 and/or CD123-specific CAR gene-engineered T cells)

Acute Myeloid Leukemia · CD33

#CD33#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleShenzhen Geno-Immune Medical In…Phase 1

CLL-1, CD33, CD38 and/or CD123-specific universal CAR- T cells (CLL-1, CD33, CD38 and/or CD123-specific universal CAR- T cells)

Acute Myeloid Leukemia · CD33

#CD33#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleBaylor College of MedicinePhase 1

CLL-1.CAR T cells (CLL-1.CAR T cells)

Acute Myeloid Leukemia · Acute Myeloid Leukemia

#AcuteMyeloidLeukemia#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 1Status Recruiting
CGTLimited DatastaleZhejiang UniversityPhase 1

CLL1 CAR T-cells (CLL1 CAR T-cells)

AML · AML

#AML#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 1Status Active
CGTLimited DatastaleZhejiang UniversityPhase 1

CLL1 CAR-T (CLL1 CAR-T)

AML · AML

#AML#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 1Status Active
CGTLimited DatastaleGuangzhou Bio-gene Technology C…Preclinical

CLL1+CD33 CAR-T (CLL1+CD33 CAR-T)

Acute Myeloid Leukemia · CD33

#CD33#CGT#Preclinical#cell-gene-therapy#CAR-T+3
Trials 1Status Discontinued

1 / 2 pages

← PreviousNext →